688 related articles for article (PubMed ID: 15482514)
1. Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren.
Roost HP; Gassner M; Grize L; Wüthrich B; Sennhauser FH; Varonier HS; Zimmermann H; Braun-Fahrländer Ch;
Pediatr Allergy Immunol; 2004 Oct; 15(5):401-7. PubMed ID: 15482514
[TBL] [Abstract][Full Text] [Related]
2. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
Bernsen RM; van der Wouden JC
Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
[TBL] [Abstract][Full Text] [Related]
3. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
4. No epidemiological evidence for infant vaccinations to cause allergic disease.
Koppen S; de Groot R; Neijens HJ; Nagelkerke N; van Eden W; Rümke HC
Vaccine; 2004 Sep; 22(25-26):3375-85. PubMed ID: 15308362
[TBL] [Abstract][Full Text] [Related]
5. Acute infections, infection pressure, and atopy.
Paunio M; Peltola H; Virtanen M; Leinikki P; Makela A; Heinonen OP
Clin Exp Allergy; 2006 May; 36(5):634-9. PubMed ID: 16650049
[TBL] [Abstract][Full Text] [Related]
6. Allergic disease and atopic sensitization in children in relation to measles vaccination and measles infection.
Rosenlund H; Bergström A; Alm JS; Swartz J; Scheynius A; van Hage M; Johansen K; Brunekreef B; von Mutius E; Ege MJ; Riedler J; Braun-Fahrländer C; Waser M; Pershagen G;
Pediatrics; 2009 Mar; 123(3):771-8. PubMed ID: 19255001
[TBL] [Abstract][Full Text] [Related]
7. Allergic disease and sensitization in Steiner school children.
Flöistrup H; Swartz J; Bergström A; Alm JS; Scheynius A; van Hage M; Waser M; Braun-Fahrländer C; Schram-Bijkerk D; Huber M; Zutavern A; von Mutius E; Ublagger E; Riedler J; Michaels KB; Pershagen G;
J Allergy Clin Immunol; 2006 Jan; 117(1):59-66. PubMed ID: 16387585
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
9. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
[TBL] [Abstract][Full Text] [Related]
10. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
Alfredsson R; Svensson E; Trollfors B; Borres MP
Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
[TBL] [Abstract][Full Text] [Related]
11. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection.
Olesen AB; Juul S; Thestrup-Pedersen K
Acta Derm Venereol; 2003; 83(6):445-50. PubMed ID: 14690341
[TBL] [Abstract][Full Text] [Related]
12. Infant immunization and the occurrence of atopic disease in Dutch and German children: a nested case-control study.
Mommers M; Weishoff-Houben M; Swaen GM; Creemers H; Freund H; Dott W; van Schayck CP
Pediatr Pulmonol; 2004 Oct; 38(4):329-34. PubMed ID: 15334511
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
14. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.
Pool V; Braun MM; Kelso JM; Mootrey G; Chen RT; Yunginger JW; Jacobson RM; Gargiullo PM;
Pediatrics; 2002 Dec; 110(6):e71. PubMed ID: 12456938
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
18. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
20. The two-dose measles, mumps, and rubella (MMR) immunisation schedule: factors affecting maternal intention to vaccinate.
Pareek M; Pattison HM
Br J Gen Pract; 2000 Dec; 50(461):969-71. PubMed ID: 11224968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
